Loading...
OTC Markets
Totals
Securities
12,222
Dollar Vol
$2.1B
Share Vol
2.3B
Trades
291,758

OTC Markets Group uses cookies and similar technologies to help us understand how you use our websites, as further disclosed in our Privacy Policy. Our Terms of Service contain important information including restrictions on your use of our websites. By clicking “Accept”, or by continuing to use our websites, you consent to the use of cookies and agree to the terms of the OTC Markets Group Privacy Policy and Terms of Service.

INRLF
Valneva SE

Ordinary Shares

3.00

0.11

3.81%

2.83 / 3.19 (1 x 1)

Real-Time Best Bid & Ask: 03:01pm 07/22/2025
Delayed (15 Min) Trade Data: 11:31am 07/22/2025
Valneva SE Company Logo

6 rue Alain Bombard

Saint-Herblain 44800

France

Last Verified 01/2013
Business Description
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also develops VLA15, a vaccine candidate against Borrelia, the bacterium that causes Lyme disease; S4V2, a tetravalent ...
More
Financial Reporting
Reporting Status
International Reporting: Euronext Paris
Audited Financials
Audited
CIK
0001432401
Fiscal Year End
12/31
Company Officers & Contacts
Thomas Szucs
Chairman of the Supervisory Board

Thomas Lingelbach
CEO

Ernst-Gunter Afting
Bankruptcy Plan Admin.

Reinhard Kandera
CFO

Board of Directors
Ernst-Gunter Afting

Alexander von Gabain

Michel Greco

James Sulat

James Sulat has served as a director of the Company since January 2015. Mr. Sulat served as Chair of the Board of Directors for Momenta Pharmaceuticals, Inc., a leader in the analysis, characterization and design of complex pharmaceutical products, since 2008, as the Vice Chair of the Supervisory Board for Valneva SE, a biotech company focusing on vaccines, since 2013, and as a member of the Board of Directors for AMAG Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of specialty pharmaceutical products, since 2014. Previously, Mr. Sulat served as the Chief Executive Officer and Chief Financial Officer of Maxygen, Inc., a biopharmaceutical company, from October 2009 to June 2013. Mr. Sulat also served as a member of the Board of Directors of Maxygen, Inc., from October 2003 to June 2013. Prior to that, he served as the Chief Financial Officer of Memory Pharmaceuticals Corp., a biopharmaceutical company, from February 2008 through September 2008, as Memory Pharmaceuticals Corp.'s President and Chief Executive Officer from May 2005 through February 2008 and as a member of the Board of Directors of Memory Pharmaceuticals Corp. from May 2005 through January 2009. Mr. Sulat received a B.S. in Administrative Sciences from Yale University, and an M.B.A. and an M.S. in Health Services Administration from Stanford University.

Hans Wigzell

Other Company Insiders

Not available

Other Company Insiders are all persons or entities beneficially owning 10% or more of any class of the issuer's securities. Together, officers, directors and other company insiders comprise Company Insiders.
Service Providers

Not available

Profile Data
SIC - Industry Classification
2834 - Pharmaceutical preparations
Incorporation Information
AT, 1998
Employees
400 as of 06/30/2010
Shell
No
Products and Services

Not available

Company Facilities

Not available

Company Notes
Formerly=Intercell AG until 6-2013
The Pink Limited Market is for broker-dealers to publicly quote securities with limited to no issuer involvement. Pink Limited companies do not certify their compliance with established reporting standards, have limited availability of disclosure or financial information and may not support their U.S. market. These securities are identified with a yield sign to warn investors to proceed with caution.
Limited Information Icon
Pink Limited Information
Securities
Other Valneva SE Securities
Daily Advancers
Subscribe to Our Newsletter
Stay up to date on the latest company news, industry trends and regulatory changes that affect our markets and learn about members of our community.